Abstract: Recently, crossbar array based in-memory accelerators have been gaining interest due to their high throughput and energy efficiency. While software and compiler support for the in-memory ...

SHENZHEN, China, March 4, 2026 /PRNewswire/ -- MicroCloud Hologram Inc. (NASDAQ: HOLO), ("HOLO" or the "Company"), a technology service provider, released a core quantum machine learning technology ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Machine learning is an essential component of artificial intelligence. Whether it’s powering recommendation engines, fraud detection systems, self-driving cars, generative AI, or any of the countless ...

Amid a push toward AI agents, with both Anthropic and OpenAI shipping multi-agent tools this week, Anthropic is more than ready to show off some of its more daring AI coding experiments. But as usual ...

With countless applications and a combination of approachability and power, Python is one of the most popular programming languages for beginners and experts alike. We’ve compiled a list of 10 online ...

Abstract: Generating high-performance tensor programs on resource-constrained devices is challenging for current Deep Learning (DL) compilers that use learning-based cost models to predict the ...

The native just-in-time compiler in Python 3.15 can speed up code by as much as 20% or more, although it’s still experimental. JITing, or “just-in-time” compilation, can make relatively slow ...

FDA accepted Replimune’s resubmitted Biologics License Application for RP1 combined with Bristol Myers Squibb’s Opdivo to treat advanced melanoma The agency set April 10, 2026 as the decision deadline ...

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the ...

Replimune (NASDAQ:REPL) announced on Tuesday that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding its marketing application for its lead asset, RP1, declining ...